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Tumor microenvironment constitutes a complex network in which tumor cells communi­
cate among them and with stromal and immune cells. It has been shown that cancer 
cells are able to exchange genetic materials through small extracellular vesicles (EVs), 
a heterogeneous group of vesicles with different size and shape, cargo content, and 
function. The importance to investigate populations of circulating EVs would be of great 
importance as prostate cancer (PCa) biomarkers. In several neoplasms as well as in 
PCa, nanometer­sized EVs of endosomal origin are implicated in supporting tumor 
growth and metastatic spread by both altering local stroma cells and creating a protumor 
environment that favors the formation of pre­metastatic niches. Several techniques are 
applicable for the isolation and analysis of PCa­derived small EVs and are illustrated in 
this article. Due to the high sensitivity and specificity of these techniques, small EVs have 
become ideal candidates for early diagnosis. Moreover, we discuss the role of small EVs 
during PCa carcinogenesis, as well as in modulating the development of drug resistance 
to hormonal therapy and chemotherapy, thus underlining the potential of EV­tailored 
strategies in PCa patients.
Keywords: prostate cancer, drug resistance, tumor microenvironment, tumor biomarkers, small extracellular 
vesicles
inTRODUCTiOn
Tumor microenvironment components represent promising therapeutic targets in cancer. 
Indeed, it is implicated in tumor carcinogenesis and progression, as well as in the suppression of 
antitumor immune response and in the development of drug resistance (1). These activities are 
the result of a complex network between normal and cancer cells, which supports tumor prolife­
ration and metastatic spread. Recently, it has been shown that cancer cells are able to exchange 
genetic materials through extracellular vesicles (EVs), a heterogeneous group of vesicles with 
different size and shape, cargo content, and function (2).
Among them, nanometer­sized EVs of endosomal origin are involved in promoting tumor growth 
and metastasis (3) through the alteration of local stroma cells (4) and the creation of a protumor 
environment that sustains the formation of pre­metastatic niches (5, 6). These small size vesicles 
of ~30–150 nm in diameter are released into the extracellular space after fusion of multivesicular 
Table 1 | Overview of various small extracellular vesicles (EVs) isolation techniques.
isolation method Principle Processing 
time
advantages Disadvantages Purity degree Reference
Ultracentrifugation Sedimentation  
rates (depending  
on size and shape)
3–16 h Easy to use,  
high yields
High equipment cost,  
time­consuming, low portability,  
not scalable, high­speed  
centrifugation may induce  
vesicle disruption
Low: contamination by  
cell debris, large vesicles, 
vesicle aggregates, and 
protein complexes
(12–16)
Density gradient 
separation
Density 20–24 h Adequate grade  
of purity
Laborious and time­ 
consuming, low portability,  
not scalable
Medium: contamination  
by high­density lipoprotein  
and other vesicles
(17–20)
Ultrafiltration Size 1–6 h Fast, good portability,  
useful for urine  
concentration
High­speed centrifugation  
may induce vesicle disruption,  
membrane filter clogging,  
small EVs loss, not scalable
Low: protein  
co­isolation
(12, 21)
Size­exclusion 
chromatography
Size 6–12 h Gravity flow preserves  
small EVs integrity,  
high reproducibility
Not scalable, time­consuming High (22)
Small EVs  
precipitation
Polymer mixtures  
that alter the solubility  
of small EVs
30 min–2 h Fast, easy to use, no  
specialized equipment  
required, large and  
scalable sample capacity
Low purity, not recommended  
if coupled with mass  
spectrometry
Low: contamination  
by protein aggregates  
and other vesicles
(23–25)
Immunoaffinity  
capture
Presence of small  
EVs’ surface antigens
16–20 h Unique method for  
the isolation of specific  
small EVs
High reagent cost,  
low capacity, low yields,  
time­consuming
Very high (26–29)
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bodies with the cell membrane and could be found in blood, 
urine, and other biological fluids. Urine EVs have been shown to 
contain RNA, DNA, and miRNA, lipid and proteins/transporters 
specific to cells of the kidney and urogenital tract. Thus, urine 
represents a potentially useful non­invasive material for diag­
nosis and prognosis of genitourinary tract neoplasms (7, 8). Due 
to their involvement in the early phases of tumor development 
and dissemination, future diagnostic and therapeutic EV­tailored 
strategies are emerging in the armamentarium of cancer patients.
In genitourinary tumors, EVs represent potential novel bio­
markers. Indeed, small EVs have been involved in kidney diseases 
and cancer, as well as in bladder cancer growth and progression 
(9). In prostate cancer (PCa), small EVs have been reported to 
contain high levels of molecules that stimulate cancer cell inva­
sion, such as integrins β4 (ITGB4) and αvβ6, vinculin (VCL), 
transmembrane glycoprotein Trop­2, vimentin, and N­cadherin, 
well­known epithelial–mesenchymal transition markers (6, 10).
Furthermore, the efficacy of urine assays in PCa diagnostic 
could be improved by simple procedures like prostate massage 
to increase the amount of tumor­specific nucleic acids released 
(11). This review illustrates the main techniques for isolation and 
analysis of small EVs and emphasizes their role in the carcino­
genesis, progression, and drug response in patients with prostate 
tumor, thus underlying the potential of emerging EV­tailored 
approaches in this setting.
iSOlaTiOn OF PCa SMall evs
The currently adopted methods for small EVs isolation include 
differential and density gradient ultracentrifugation, size­based 
methods (ultrafiltration and size­exclusion chromatography), 
polymer­based precipitation, and immunoaffinity capture. The 
choice of the isolation technique depends on the sample source, 
the sample amount, the type of the downstream molecular 
analyses, the desired purity level, and final concentration. Each 
method shows both advantages and disadvantages, summarized 
in Table 1. It should be noted that some isolation methods can 
be more easily integrated with analysis of vesicular RNAs and 
proteins, so fewer steps are needed. This can therefore improve 
the reliability and efficiency of small EVs analysis.
Ultracentrifugation
Ultracentrifugation is the most frequently used approach for 
small EVs isolation, mainly since it does not require high level 
of technical experience. This technique is based on the different 
sedimentation rates (depending on size and density) of small 
EVs from the other sample components (12). Generally, before 
ultracentrifugation, some steps of low­speed centrifugation 
(3,000–20,000 ×  g) are carried out to clean the sample from 
large particles, including cells, platelets, apoptotic bodies, and 
microvesicles. Typically, for ultracentrifugation, the used force 
ranges from 100,000 to 200,000 ×  g. Due to the high­speed 
centrifugation, the small EVs rupture represents a high risk 
and leads to the yield reduction of intact particles suitable for 
downstream analyses. It also requires high volumes of samples, 
it is time­consuming and not suitable for large number of 
samples (13).
Moreover, pellet obtained by this method may contain also 
EV aggregates and protein complexes similar to small EVs in size 
(14). A particular case regards the uromodulin (THP), which is 
the most abundant protein in urine and can form a polymeric 
network that facilitates small EVs’ aggregation. Uromodulin 
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removal and the consequent increase of small EVs’ yield can be 
achieved by using the detergent CHAPS or the reducing agent 
dithiothreitol in urine samples (15). Finally, unlike free RNA that 
is degraded by urinary RNAses, DNA contamination is frequent, 
and a DNAse should be used if small EVs’ DNA is the target of 
downstream analyses (16).
Density Gradient Centrifugation
The density gradient centrifugation method allows small EVs 
separation from other sample components by exploiting their 
typical density, which ranges between 1.13 and 1.19 g/ml (17). 
By using pre­constructed columns composed of solutions with 
different densities, after ultracentrifugation small EVs will be at a 
specific column layer.
It allows purer small EVs isolation than simple ultracentrifu­
gation; in fact, it is generally used as a second step after other 
isolation methods to purify the extracts (18, 19). However, 
high­density lipoproteins represent a contaminant frequently 
co­isolated with small EVs; therefore, plasma and serum are 
not suitable sample types for density gradient centrifugation. In 
addition, it cannot distinguish small EVs from other EVs with 
similar density (20).
Ultrafiltration
Ultrafiltration represents an efficient alternative to ultracen­
trifugation. It involves the use of nanomembrane filters of poly­
ethersulfone or polyvinylidene difluoride with an approximately 
50–100  kDa molecular mass cutoff (12). Generally, some steps 
of filtration with membrane filters having larger pores can be 
performed for the depletion of floating cells and large cell debris 
(21). Membranes allow the concentration of very diluted samples 
and therefore they are especially suited for cell culture media and 
urine samples.
Extracellular vesicles size can be also exploited by the 
size­exclusion chromatography that, using sepharose packed 
columns, allows the separation of the small EVs fraction from 
biofluids, with high purity and reproducibility (22). However, 
both ultrafiltration and size­exclusion chromatography have 
long run times that limit their scalability for clinical routine 
laboratory applications.
Precipitation Methods
Some isolation kits for small EVs precipitation are commercially 
available (23, 24). They are based on water­excluding polymer 
mixtures that force insoluble components out. When these 
polymers are added to the sample and after a low­speed ultracen­
trifugation (<20,000 × g), they allow the precipitation of small 
EVs. Since precipitation method is very fast, easy to use, and no 
equipment is necessary, it is a method scalable for large sample 
sizes and therefore is suited for the clinical use.
Recently, performances of ultracentrifugation and four dif­
ferent precipitation methods have been assessed in urine sam­
ples. In this comparison, a precipitation method outperforms 
the others in detecting alterations of PCa small EVs’ markers 
(25). However, other EVs are frequently co­isolated, making this 
procedure not so specific for small EVs. Moreover, abundant 
proteins, including uromodulin, can also be recovered.
immunoaffinity isolation Methods
Finally, immunoaffinity isolation methods exploit the presence 
of specific proteins in the small EVs’ surface (26). Antibodies 
conjugated with magnetic beads or other materials can recog­
nize the vesicular antigens and facilitate the precipitation by 
low­speed centrifugation or the isolation by magnetic tech­
niques. This method is highly specific, allowing the isolation 
of only small EVs by using general small EV surface markers 
(e.g., CD81, CD9, and CD63) and even only small EV subpopula­
tions, for example, tumor small EVs by using a tumor­specific 
marker.
Recently, specific methods for immuno­based small EVs isola­
tion and detection for PCa have been proposed, both measuring 
total small EVs (27) and exploiting the anti­prostate­specific 
membrane antigen (PSMA) antibody (28). Moreover, it has 
been observed that immunoaffinity­based methods have better 
performance than purification methods in isolating PCa small 
EVs from patient plasma samples (29). However, this generally 
leads to low yields. In addition, immunoaffinity isolation requires 
several elaboration steps making it subjected to potential errors 
by operators.
analYSiS OF PCa SMall evs
After isolation, small EVs quantity, size, purity, and other prop­
erties can be assessed. A popular method to quantify total small 
EVs is the nanoparticle tracking analysis (NTA) (12, 30–32). 
It also allows the determination of a size distribution profile of 
particles in solution and, by verifying that the observed distribu­
tion ranges within typical small EV size, also the purity degree 
can be estimated. In particular, a laser beam makes particles 
visible and therefore their concentration can be assessed. The 
size distribution can be evaluated by measuring the velocity 
of the Brownian motion of each particle and, according to the 
Stokes–Einstein equation, speed of particles can be correlated 
to the particle size. However, protein complexes, lipoprotein 
particles, and vesicle aggregates similar to small EVs in size can 
be revealed by NTA and therefore the small EVs concentration 
could be overestimated. Flow cytometry is another popular 
method for both small EVs quantification and characterization 
(33). In particular, particles are illuminated by a laser beam, 
and the scattered light is detected. However, currently, there is a 
detection limit of 150 nm; therefore, the use of latex or magnetic 
beads coupling with small EVs is suggested to make these aggre­
gates visible by flow cytometry (34). Flow cytometry has been 
used to perform “liquid biopsy” in PCa patient plasma samples. 
Biggs et  al. measured circulating prostate microparticles 
(PMPs), a type of EVs, with a size ranging from 100 to 1,000 nm, 
immunoreactive to anti­PSMA mAb. PMP enumeration levels 
in plasma permit to identify patients with Gleason score ≥8 PCa 
independently from PSA value (35).
Regarding small EVs quantification, researchers frequently 
adopt the enzyme­linked immunosorbent assay (ELISA). 
Similar to immunoaffinity isolation methods, this approach 
exploits small EV surface antigens that can be detected by 
specific antibodies. To quantify total small EVs, CD63, CD9, 
and CD81 vesicular­specific proteins are generally measured 
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by ELISA (34). The evaluation of the enzymatic activity of the 
acetyl­CoA acetylcholinesterase, which is enriched in small EVs, 
is another method used for quantification and purity assess­
ments. Alternatively, to evaluate the purity degree of a small EVs 
preparation, Western blotting can be used to assess the presence 
of typical small vesicular proteins (CD63, CD9, CD81, Alix, and 
Tsg101) (12). However, this assay is not quantitative and gives no 
information on the particle size.
Upon small EVs isolation and quantification, their RNA, 
DNA, protein, and lipid content can be analyzed. RNA profiling 
can include mRNAs and miRNAs and can be achieved both 
by PCR­based assays for single RNA molecule profiling and by 
next­generation sequencing (RNA­seq) for large­scale analysis. 
For example, after isolation of small EVs in urine specimens, 
the levels of PCa­associated mRNA transcripts in these vesicles 
have been assessed by quantitative real­time PCR analysis 
(36, 37). In addition, quantification of vesicular miRNAs can 
be assessed by RNA­seq, as carried out for urinary small EVs 
from PCa patients (38). However, vesicular miRNA quanti­
fication can be affected by inadequate procedural choices, 
including the choice of optimal endogenous miRNA for expres­
sion normalization (39). Differential expression analysis of 
vesicular mRNAs or miRNAs between samples from primary 
PCa, metastatic cancers, and healthy subjects can lead to the 
identification of candidate biomarkers (40). In addition, other 
gene expression analysis methods, including co­expression 
network analysis, can suggest potential diagnostic and prognos­
tic biomarkers (41–43). Analysis of urinary vesicular RNA and 
DNA has also been performed in prostate tumors to identify 
the presence of mutations (44). It has been observed that small 
EVs released by different PCa cell lines harbor specific DNA 
mutations (45). These results may allow the development of 
non­invasive tests for mutational status assessment in PCa. 
Interestingly, the specific molecular effects due to the identified 
mutations on transcription, splicing, miRNA binding at 3′UTR, 
and nucleocytoplasmic export of mRNA can be effectively 
predicted (46–49).
Furthermore, methods for single protein and multiple pro­
tein profiling exist. Western blot, cytofluorimetry, and ELISA 
represent popular methods for the assessment of specific small 
vesicular proteins and for validation of results obtained by 
other proteomic methods, also regarding urinary small EVs of 
PCa patients (50). Recently, a new aptamer­based method for 
the simultaneous analysis of around 1,000 proteins from small 
EVs of PCa patients has been developed (51). Moreover, mass 
spectrometry has been frequently used to identify all small 
EVs’ proteins from many sample types and, recently, it has also 
been exploited for the analysis of small EVs’ proteins in plasma 
samples of PCa patients (52). Interestingly, mass spectrometry 
can be also used to assess the lipid content of small EVs. In par­
ticular, lipid species in small EVs released by PCa cell lines and 
present in urine of PCa patients have been evaluated (53, 54). 
It should be also taken into account the heterogeneous nature 
of cancer EVs; different types of PCa cells are more prone to 
shed heterogeneous populations of EVs compared with other 
PCa cells. Indeed, El­Sayed and her group have recently showed 
mesenchymal­like prostate carcinoma cells have a propensity to 
release EVs of varied sizes with diameters ranging from 100 to 
300 nm approximately, while epithelial­like PCa cells principally 
generate small vesicles (50–150 nm). The isolation method could 
be a technical limitation; further studies are needed to properly 
characterize and classify these vesicles and to investigate the 
potential effects of EVs as a whole, including small EVs’ fraction 
and others EVs’ subgroups (10).
eXPlORinG SMall evs in PCa PaTienTS
Small evs and PCa Diagnosis
In the past 10 years, small EVs have emerged as a novel effec­
tive and non­invasive clinical tool for the screening and early 
diagnosis of PCa. This evidence is supported by the specificity 
and sensitivity showed by small EVs analysis in this disease, 
together with the possibility of a non­invasive assessment of 
gene expression and mutations (36), thus leading to a year­by­
year growing number of studies in this context. Indeed, it has 
been shown that only PCa patients are characterized by high 
levels of nanovesicles (125–180 nm, i.e., small EVs) expressing 
both CD81 and PSA (55). Such results were obtained analyzing 
1 ml of plasma samples of 15 healthy donors, 15 benign prostatic 
hyperplasia, and 15 PCa patients by nanoscale flow cytometry 
and ELISA assay. Moreover, McKiernan and his group revealed 
that gene expression assay in urine small EVs was able to dis­
criminate high­grade (Gleason score ≥7) from low­grade (GS6) 
cancer and benign disease. Small EVs’ RNA cycle threshold 
values of ERG, PCA3, and SPDEF were used to derive urine 
small EVs gene expression assay score that was tested in 255 
men and then was prospectively validated in an independent 
cohort of 519 men. In this way, they identified patients with 
higher­grade PCa among men with elevated PSA levels, thus 
potentially reducing the number of unnecessary biopsies (56). 
In the same view, high Claudin 3 levels from isolated small 
EVs were able to predict GS ≥8 (57), while small EVs’ levels 
of gamma­glutamyltransferase 1, a cell­surface enzyme that 
regulates the catabolism of extracellular glutathione, were 
significantly higher in PCa patients compared with benign 
prostatic hyperplasia patients (58).
Interestingly, several miRNAs from isolated urinary small 
EVs, such as miR­2909 (59), miR­19b (60), miRNA­21, and 
miR­375 (61), have demonstrated to be effective as diagnostic 
biomarkers for prostate tumors. The isolation method used in 
these studies included precipitation of small EVs in fluids with 
low­speed centrifugation step (59) or differential centrifugation 
(60, 61) with selection of vesicles of 30–100  nm obtained by 
0.1­µm filtration (60). The authenticity of these isolated small 
EVs was confirmed by subjecting them to morphological analysis 
by electronic microscopy (59, 61), immunostaining with anti­
bodies against CD63, CD9, and CD24 (60), or Western blot 
analysis using CD63 antibody coupled with standard immuno­
detection procedure (59).
More recently, the analysis of the lipidome of urinary small 
EVs showed statistically significant difference between PCa 
patients (n = 15) and healthy volunteers (n = 13), in particular 
for the high presence of phosphatidylserine and lactosylceramide 
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associated with PCa diagnosis (53). These pioneering studies, 
even if limited to a small number of samples, are promising and 
should be validated in larger independent cohorts.
Small evs and PCa Development  
and Progression
Prostate cancer­derived small EVs are directly involved in PCa 
carcinogenesis and metastasis. Indeed, small EVs are able to 
significantly reduce apoptosis, increase cancer cell prolifera­
tion, and induce cell migration in LNCaP and RWPE­1 cells 
(62). Moreover, they can modulate bone cell formation by affec­
ting the fusion and differentiation of osteoclasts in the meta­
static sites (63), thus favoring the formation of pre­metastatic 
niches.
Hypoxia plays a crucial role in regulating small EVs activity. 
In fact, it has been shown that small EVs secreted by PCa cells 
under hypoxic conditions showed higher metalloproteinases 
(MMPs) activity and increased levels of proteins primarily 
implicated in the remodeling of epithelial adherens junction 
pathway compared with small EVs released from normoxic cells. 
Therefore, this enhanced the invasiveness and stemness of naïve 
PCa cells (64).
Beyond their potential use for PCa diagnosis, miRNAs are 
directly implicated in PCa development and progression. It has 
been shown that normal prostate fibroblasts (WPMY­1) trans­
fected with miR­100­5p, miR­21­5p, and miR­139­5p augmented 
their migration and metastatic invasion by increasing the expres­
sion of MMP­2, ­9, and ­13 and RANKL (65). Furthermore, 
adipocyte differentiation­related protein can be detected in 
small EVs released by PCa cells and is able to induce neuroen­
docrine differentiation of these cells in a paracrine fashion (66). 
Interestingly, small EVs are also involved in modulating PCa­
induced immunosuppression of dendritic cell functions (67) and 
promote immune evasion by downregulating NKG2D expression 
on natural killer cells and CD8+ T cells (68).
Even if most of the studies on biological effects of small EVs 
are conducted in  vitro, they lay the foundations for following 
clinical investigations.
Recently, it has been shown that the expression of CD9 is 
increased in PCa of patients who suffer from disease recurrence 
in 5 years, indicating the role of CD9 in the progression of recur­
rent advanced PCa (69).
Using the established immunocapture and immunodetection 
method, Soekmadji and colleagues reported that the level of 
CD9+ EVs in plasma is increased in PCa patients compared 
to those with benign prostate hyperplasia and, on the contrary, 
CD63+ EVs level does not show a significant difference between 
the two groups. Moreover, they showed that in plasma obtained 
from a metastatic PCa patient cohort the level of CD9+ EVs 
were higher in circulating tumor cell (CTC)­positive PCa 
patients compared with CTC­negative patients. Instead, the 
CD63+ EVs level did not show significant differences between 
the cohorts (70, 71).
Such findings underline the importance to investigate par­
ticularly subpopulations of circulating EVs that would be more 
informative as PCa biomarkers.
Therapeutic Potential of Small evs and 
Drug Resistance in Patients with PCa
The stability and low immunogenicity of EVs support their 
use as therapeutic delivery agents for cancer drugs and small 
molecules. The methodology for loading EVs with a thera­
peutic cargo consists into two different approaches: the first 
one is based on the indirect modification of EV membranes via 
the genetic engineering of their parental cell (72). The second 
one needs the direct encapsulation of a cargo into purified 
exosomes through active (i.e., sonification and electroporation) 
or passive (i.e., the introduction of hydrophobic drugs into 
EVs, the utilization of multivalent electrostatic interactions, 
permeabilization with saponin) loading methods (72). These 
technologies will represent a major step forward in the era of 
precision medicine for PCa patients and should be tested into 
future clinical trials.
Small EVs have been shown to be crucial for the develop­
ment of drug resistance in patients with prostate tumor. 
In 2017, Del Re et al. assessed AR­V7 as a predictor of resist­
ance to hormonal therapy by highly sensitive digital droplet 
polymerase chain reaction in plasma­derived small EVs’ RNA. 
They found that both median progression­free survival (20 vs. 
3  months; p <  0.001) and overall survival (8 months vs. not 
reached; p < 0.001) were significantly longer in AR­V7­negative 
vs. AR­V7­positive patients (73).
Small EV­derived microRNAs contribute also to PCa chem­
oresistance (74) and can act as surrogate biomarker of tumor 
response to taxanes (75). It has been observed that the transfer 
of small EVs (in particular, small EVs’ MDR­1/P­gp) from 
docetaxel­resistant cell lines to DU145, 22Rv1, and LNCap PCa 
cell lines induces acquired resistance to this drug (76). In the 
same view, Kawakami et al. reported that β4 (ITGB4) and VCL in 
small EVs could be useful markers of PCa progression correlated 
with taxane resistance (77).
Interestingly, serum small EVs’ P­glycoprotein high levels 
are associated with resistance to docetaxel but not to cabazitaxel 
(78), thus representing a potential biomarker to guide the 
decision­making process in PCa patients.
Another important therapeutic use of EVs is vaccination to 
treat cancer. It has already been studied on mice injected with 
autologous tumor­derived nanovesicles, enriched with tumor­
specific antigens. The high­level immunogenicity of these 
nano vesicles induced an antitumor immune responses in both 
primary and metastatic melanoma mouse models (79).
Some questions have to be answered before these preclini­
cal evidences on EV­based therapy can be applied in a clinical 
scenario. Major problems are the EV’s production, purification, 
and concentration, the biodistribution of EVs, the targeting of 
recipient cells, the up­taking by the recipient cells, and the effects 
on the recipient immune system (80).
DiSCUSSiOn anD COnClUSiOn
For years, Gleason score has represented the most relevant 
prognostic factor in patients with PCa, along with PSA levels 
measured at the time of diagnosis and the TNM score. Plasma 
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FiGURe 1 | Functions exerted by small extracellular vesicles (EVs) in prostate cancer (PCa) microenvironment and their clinical implications.
quantification of PSA has markedly improved the early detec­
tion of PCa, but still lacks the required specificity. More recently, 
a new generation of potentially predictive and prognostic 
parameters has grown, opening the way to molecularly tailored 
approaches in PCa patients. Small EVs have been reported to act 
as mediators of cell­to­cell communication due to the regulatory 
functions of their content. The high sensitivity and specificity of 
data obtained from small EVs analysis, their presence in almost 
all human fluids, and the variety of their functions exerted 
during tumor carcinogenesis, progression, and response to 
treatments, support the notion that small EVs exploration will 
represent a cornerstone of future approaches in cancer patients. 
Further investigations are needed, particularly regarding the 
content of the different EVs and their possible use in clinical 
and therapeutic settings.
The current application of EVs engineering is limited by a 
series of key factors that should be overcrossed to introduce 
these methodologies into daily clinical practice. Among them, 
a standardization of present methods of isolation and analysis 
results fundamental. Interestingly, EVs is a wide term that 
includes different vesicle types such as exosomes, microvesi­
cles, and apoptotic bodies. This nomenclature, based on size, 
biogenesis, and cellular release mechanisms, is currently not 
consistent throughout the literature (17, 81, 82). Although 
the International Society of EVs (ISEV) is making an effort 
to unify this controversial nomenclature, favoring the term 
EVs instead of exosomes and of other terms, a consensus 
criterion does not still exist (82). ISEV is involved also in the 
standar dization of the methodologies of EVs isolation and 
charac terization (81). Also in this case, there are not com­
monly accepted procedures. The lack of a consensus regarding 
EVs isolation and even storing conditions (83) can result in 
impure exosome preparations, raising a possible explanation 
regarding some inconsistent results in literature.
In conclusion, the search for effective predictive and 
prognostic factors in prostate neoplasms is still ongoing. The 
growing knowledge about molecular biology of this tumor is 
bringing us very rapidly to a new age of therapeutic possibilities. 
Nevertheless, the cost–benefit ratio of the massive application of 
these new potential prognostic factors represents a crucial point 
in the choice of the “best one.” Based on this scenario, small 
EVs may represent a cornerstone in the future diagnostic and 
treatment­decision processes of PCa, leading to a more tailored 
and personalized approach for patients with advanced disease 
(Figure 1) (84).
aUTHOR COnTRibUTiOnS
RM and MS (Marina Scarpelli): conception and design. MG and 
MS (Matteo Santoni): drafting the manuscript. FC, FP, and AC: 
review of the literature. LC, NB, and AL­B: critical revision of the 
manuscript.
7Giulietti et al. Small EVs in PCa
Frontiers in Oncology | www.frontiersin.org June 2018 | Volume 8 | Article 221
ReFeRenCeS
1. Langley RR, Fidler IJ. The seed and soil hypothesis revisited – the role of 
tumor­stroma interactions in metastasis to different organs. Int J Cancer 
(2011) 128(11):2527–35. doi:10.1002/ijc.26031 
2. El Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: 
biology and emerging therapeutic opportunities. Nat Rev Drug Discov (2013) 
12(5):347–57. doi:10.1038/nrd3978 
3. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, 
and drug resistance: a comprehensive review. Cancer Metastasis Rev (2013) 
32:623–42. doi:10.1007/s10555­013­9441­9 
4. Luga V, Zhang L, Viloria­Petit AM, Ogunjimi AA, Inanlou MR, Chiu E. 
Exosomes mediate stromal mobilization of autocrine Wnt­PCP signalling 
in breast cancer cell migration. Cell (2012) 151:1542–56. doi:10.1016/j.cell. 
2012.11.024 
5. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa­Silva B, Moreno­Bueno G, 
et  al. Melanoma exosomes educate bone marrow progenitor cells toward 
a pro­metastatic phenotype through MET. Nat Med (2012) 18:883–91. 
doi:10.1038/nm.2753 
6. Chowdhury R, Webber JP, Gurney M, Mason MD, Tabi Z, Clayton A. Cancer 
exosomes trigger mesenchymal stem cell differentiation into pro­angiogenic 
and pro­invasive myofibroblasts. Oncotarget (2015) 6:715–31. doi:10.18632/
oncotarget.2711 
7. Pisitkun T, Shen R­F, Knepper MA. Identification and proteomic profiling of 
exosomes in human urine. Proc Natl Acad Sci U S A (2004) 101:13368–73. 
doi:10.1073/pnas.0403453101 
8. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, Kleta R, et al. 
Large­scale proteomics and phosphoproteomics of urinary exosomes. J Am 
Soc Nephrol (2009) 20:363–79. doi:10.1681/ASN.2008040406 
9. Nawaz M, Camussi G, Valadi H, Nazarenko I, Ekström K, Wang X, et  al.  
The emerging role of extracellular vesicles as biomarkers for urogenital 
cancers. Nat Rev Urol (2014) 11:688–701. doi:10.1038/nrurol.2014.301 
10. El­Sayed IY, Daher A, Destouches D, Firlej V, Kostallari E, Maillé P, et  al. 
Extracellular vesicles released by mesenchymal­like prostate carcinoma cells 
modulate EMT state of recipient epithelial­like carcinoma cells through 
regulation of AR signaling. Cancer Lett (2017) 410:100–11. doi:10.1016/j.
canlet.2017.09.010 
11. Downes MR, Byrne JC, Pennington SR, Dunn MJ, Fitzpatrick JM, Watson RWG. 
Urinary markers for prostate cancer. BJU Int (2007) 99:263–8. doi:10.1111/j. 
1464­410X.2006.06610.x 
12. Koh YQ, Almughlliq FB, Vaswani K, Peiris HN, Mitchell MD. Exosome 
enrichment by ultracentrifugation and size exclusion chromatography. Front 
Biosci (Landmark Ed) (2018) 23:865–74. doi:10.2741/4621 
13. Jeppesen DK, Hvam ML, Primdahl­Bengtson B, Boysen AT, Whitehead B, 
Dyrskjøt L, et al. Comparative analysis of discrete exosome fractions obtained 
by differential centrifugation. J Extracell Vesicles (2014) 3:25011. doi:10.3402/
jev.v3.25011 
14. Bobrie A, Colombo M, Krumeich S, Raposo G, Théry C. Diverse subpopu­
lations of vesicles secreted by different intracellular mechanisms are present 
in exosome preparations obtained by differential ultracentrifugation. 
J Extracell Vesicles (2012) 1:1. doi:10.3402/jev.v1i0.18397 
15. Musante L, Saraswat M, Duriez E, Byrne B, Ravidà A, Domon B, et al. Biochemical 
and physical characterisation of urinary nanovesicles following CHAPS treat­
ment. PLoS One (2012) 7(7):e37279. doi:10.1371/journal.pone.0037279 
16. Miranda KC, Bond DT, McKee M, Skog J, Păunescu TG, Da Silva N, et al. 
Nucleic acids within urinary exosomes/microvesicles are potential biomarkers 
for renal disease. Kidney Int (2010) 78(2):191–9. doi:10.1038/ki.2010.106 
17. van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, 
functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 
(2012) 64(3):676–705. doi:10.1124/pr.112.005983 
18. Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, 
et  al. The impact of disparate isolation methods for extracellular vesicles on 
downstream RNA profiling. J Extracell Vesicles (2014) 3. doi:10.3402/jev.v3.24858 
19. Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, et  al. 
Comparative proteomics evaluation of plasma exosome isolation tech­
niques and assessment of the stability of exosomes in normal human 
blood plasma. Proteomics (2013) 13(22):3354–64. doi:10.1002/pmic. 
201300282 
20. Böing AN, van der Pol E, Grootemaat AE, Coumans FA, Sturk A, Nieuwland R. 
Single­step isolation of extracellular vesicles by size­exclusion chromato­
graphy. J Extracell Vesicles (2014) 3. doi:10.3402/jev.v3.23430 
21. Heinemann ML, Vykoukal J. Sequential filtration: a gentle method for 
the isolation of functional extracellular vesicles. Methods Mol Biol (2017) 
1660:33–41. doi:10.1007/978­1­4939­7253­1_4 
22. Lozano­Ramos I, Bancu I, Oliveira­Tercero A, Armengol MP, Menezes­Neto A, 
Del Portillo HA, et al. Size­exclusion chromatography­based enrichment of 
extracellular vesicles from urine samples. J Extracell Vesicles (2015) 4:27369. 
doi:10.3402/jev.v4.27369 
23. Kanchi Ravi R, Khosroheidari M, DiStefano JK. A modified precipi­
tation method to isolate urinary exosomes. J Vis Exp (2015) 95:51158. 
doi:10.3791/51158 
24. Alvarez ML. Isolation of urinary exosomes for RNA biomarker discovery 
using a simple, fast, and highly scalable method. Methods Mol Biol (2014) 
1182:145–70. doi:10.1007/978­1­4939­1062­5_13 
25. Royo F, Zuniga­Garcia P, Sanchez­Mosquera P, Egia A, Perez A, Loizaga A, 
et  al. Different EV enrichment methods suitable for clinical settings yield 
different subpopulations of urinary extracellular vesicles from human 
samples. J Extracell Vesicles (2016) 5:29497. doi:10.3402/jev.v5.29497 
26. Salih M, Fenton RA, Knipscheer J, Janssen JW, Vredenbregt­van den Berg MS, 
Jenster G, et  al. An immunoassay for urinary extracellular vesicles. 
Am J Physiol Renal Physiol (2016) 310:F796–801. doi:10.1152/ajprenal. 
00463.2015 
27. Duijvesz D, Versluis CY, van der Fels CA, Vredenbregt­van den Berg MS, Leivo 
J, Peltola MT, et al. Immuno­based detection of extracellular vesicles in urine 
as diagnostic marker for prostate cancer. Int J Cancer (2015) 137:2869–78. 
doi:10.1002/ijc.29664 
28. Mizutani K, Terazawa R, Kameyama K, Kato T, Horie K, Tsuchiya T, et  al. 
Isolation of prostate cancer­related exosomes. Anticancer Res (2014) 
34:3419–23. 
29. Brett SI, Lucien F, Guo C, Williams KC, Kim Y, Durfee PN, et al. Immuno­
affinity based methods are superior to kits for purification of prostate derived 
extracellular vesicles from plasma samples. Prostate (2017) 77:1335–43. 
doi:10.1002/pros.23393 
30. Oosthuyzen W, Sime NE, Ivy JR, Turtle EJ, Street JM, Pound J, et al. Quan­
ti fication of human urinary exosomes by nanoparticle tracking analysis. 
J Physiol (2013) 591:5833–42. doi:10.1113/jphysiol.2013.264069 
31. Perrini C, Strillacci MG, Bagnato A, Esposti P, Marini MG, Corradetti B, et al. 
Microvesicles secreted from equine amniotic­derived cells and their potential 
role in reducing inflammation in endometrial cells in an in­vitro model. Stem 
Cell Res Ther (2016) 7:169. doi:10.1186/s13287­016­0429­6 
32. Lange­Consiglio A, Perrini C, Tasquier R, Deregibus MC, Camussi G, Pascucci L, 
et  al. Equine amniotic microvesicles and their anti­inflammatory potential 
in a tenocyte model in vitro. Stem Cells Dev (2016) 25:610–21. doi:10.1089/
scd.2015.0348 
33. Nolan JP, Duggan E. Analysis of individual extracellular vesicles by flow 
cytometry. Methods Mol Biol (2018) 1678:79–92. doi:10.1007/978­1­ 
4939­7346­0_5 
34. Pedersen KW, Kierulf B, Neurauter A. Specific and generic isolation of extra­
cellular vesicles with magnetic beads. Methods Mol Biol (2017) 1660:65–87. 
doi:10.1007/978­1­4939­7253­1_7 
FUnDinG
This paper was not funded. Declaration of interest: The authors 
have no relevant affiliations or financial involvement with any 
organization or entity with a financial interest in or financial 
conflict with the subject matter or materials discussed in the 
manuscript. This includes employment, consultancies, honoraria, 
stock ownership or options, expert testimony, grants or patents 
received or pending, or royalties. No writing assistance was 
utilized in the production of this manuscript.
8Giulietti et al. Small EVs in PCa
Frontiers in Oncology | www.frontiersin.org June 2018 | Volume 8 | Article 221
35. Biggs CN, Siddiqui KM, Al­Zahrani AA, Pardhan S, Brett SI, Guo QQ, et al. 
Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for 
prostate cancer using nanoscale flow cytometry. Oncotarget (2016) 7:8839–49. 
doi:10.18632/oncotarget.6983 
36. Pellegrini KL, Patil D, Douglas KJS, Lee G, Wehrmeyer K, Torlak M, et al. 
Detection of prostate cancer­specific transcripts in extracellular vesicles 
isolated from post­DRE urine. Prostate (2017) 77:990–9. doi:10.1002/
pros.23355 
37. Royo F, Zuniga­Garcia P, Torrano V, Loizaga A, Sanchez­Mosquera P, 
Ugalde­Olano A, et al. Transcriptomic profiling of urine extracellular vesicles 
reveals alterations of CDH3 in prostate cancer. Oncotarget (2016) 7:6835–46. 
doi:10.18632/oncotarget.6899 
38. Rodriguez M, Bajo­Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, et al. 
Identification of non­invasive miRNAs biomarkers for prostate cancer by 
deep sequencing analysis of urinary exosomes. Mol Cancer (2017) 16:156. 
doi:10.1186/s12943­017­0726­4 
39. Occhipinti G, Giulietti M, Principato G, Piva F. The choice of endogenous 
controls in exosomal microRNA assessments from biofluids. Tumour Biol 
(2016) 37:11657–65. doi:10.1007/s13277­016­5164­1 
40. Guo K, Liang Z, Li F, Wang H. Comparison of miRNA and gene expression 
profiles between metastatic and primary prostate cancer. Oncol Lett (2017) 
14:6085–90. doi:10.3892/ol.2017.6969 
41. Giulietti M, Occhipinti G, Principato G, Piva F. Weighted gene co­expression 
network analysis reveals key genes involved in pancreatic ductal adenocar­
cinoma development. Cell Oncol (Dordr) (2016) 39:379–88. doi:10.1007/
s13402­016­0283­7 
42. Giulietti M, Occhipinti G, Principato G, Piva F. Identification of candidate 
miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted 
gene co­expression network analysis. Cell Oncol (Dordr) (2017) 40:181–92. 
doi:10.1007/s13402­017­0315­y 
43. Huang H, Zhang Q, Ye C, Lv JM, Liu X, Chen L, et  al. Identification of 
prognostic markers of high grade prostate cancer through an integrated 
bioinformatics approach. J Cancer Res Clin Oncol (2017) 143(12):2571–9. 
doi:10.1007/s00432­017­2497­0 
44. Motamedinia P, Scott AN, Bate KL, Sadeghi N, Salazar G, Shapiro E, et al. 
Urine exosomes for non­invasive assessment of gene expression and muta­
tions of prostate cancer. PLoS One (2016) 11:e0154507. doi:10.1371/journal.
pone.0154507 
45. Lazaro­Ibanez E, Sanz­Garcia A, Visakorpi T, Escobedo­Lucea C, Siljander P, 
Ayuso­Sacido A, et  al. Different gDNA content in the subpopulations of 
prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and 
exosomes. Prostate (2014) 74:1379–90. doi:10.1002/pros.22853 
46. Giulietti M, Piva F, D’Antonio M, D’Onorio De Meo P, Paoletti D, Castrignano T, 
et  al. SpliceAid­F: a database of human splicing factors and their RNA­
binding sites. Nucleic Acids Res (2013) 41:D125–31. doi:10.1093/nar/gks997 
47. Piva F, Giulietti M, Nardi B, Bellantuono C, Principato G. An improved in silico 
selection of phenotype affecting polymorphisms in SLC6A4, HTR1A and 
HTR2A genes. Hum Psychopharmacol (2010) 25:153–61. doi:10.1002/hup.1100 
48. Piva F, Giulietti M, Occhipinti G, Santoni M, Massari F, Sotte V, et  al. 
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes 
reveals the impaired molecular processes in renal cell carcinoma. Oncotarget 
(2015) 6:32161–8. doi:10.18632/oncotarget.5147 
49. Giulietti M, Milantoni SA, Armeni T, Principato G, Piva F. ExportAid: database 
of RNA elements regulating nuclear RNA export in mammals. Bioinformatics 
(2015) 31:246–51. doi:10.1093/bioinformatics/btu620 
50. Wang L, Skotland T, Berge V, Sandvig K, Llorente A. Exosomal proteins as 
prostate cancer biomarkers in urine: from mass spectrometry discovery to 
immunoassay­based validation. Eur J Pharm Sci (2017) 98:80–5. doi:10.1016/j.
ejps.2016.09.023 
51. Welton JL, Brennan P, Gurney M, Webber JP, Spary LK, Carton DG, et  al. 
Proteomics analysis of vesicles isolated from plasma and urine of prostate 
cancer patients using a multiplex, aptamer­based protein array. J Extracell 
Vesicles (2016) 5:31209. doi:10.3402/jev.v5.31209 
52. Turay D, Khan S, Diaz Osterman CJ, Curtis MP, Khaira B, Neidigh JW, et al. 
Proteomic profiling of serum­derived exosomes from ethnically diverse 
prostate cancer patients. Cancer Invest (2016) 34:1–11. doi:10.3109/0735790
7.2015.1081921 
53. Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, 
et  al. Molecular lipid species in urinary exosomes as potential prostate 
cancer biomarkers. Eur J Cancer (2017) 70:122–32. doi:10.1016/j.ejca.2016. 
10.011 
54. Llorente A, Skotland T, Sylvanne T, Kauhanen D, Rog T, Orlowski A, et al. 
Molecular lipidomics of exosomes released by PC­3 prostate cancer cells. 
Biochim Biophys Acta (2013) 1831:1302–9. doi:10.1016/j.bbalip.2013.04.011 
55. Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, et al. 
Increased PSA expression on prostate cancer exosomes in in  vitro condi­
tion and in cancer patients. Cancer Lett (2017) 403:318–29. doi:10.1016/j.
canlet.2017.06.036 
56. McKiernan J, Donovan MJ, O’Neill V, Bentink S, Noerholm M, Belzer S, 
et  al. A novel urine exosome gene expression assay to predict high­grade 
prostate cancer at initial biopsy. JAMA Oncol (2016) 2(7):882–9. doi:10.1001/
jamaoncol.2016.0097 
57. Worst TS, von Hardenberg J, Gross JC, Erben P, Schnölzer M, Hausser I, 
et al. Database­augmented mass spectrometry analysis of exosomes identi­
fies Claudin 3 as a putative prostate cancer biomarker. Mol Cell Proteomics 
(2017) 16(6):998–1008. doi:10.1074/mcp.M117.068577 
58. Kawakami K, Fujita Y, Matsuda Y, Arai T, Horie K, Kameyama K, et al. Gamma­
glutamyltransferase activity in exosomes as a potential marker for prostate 
cancer. BMC Cancer (2017) 17(1):316. doi:10.1186/s12885­017­3301­x 
59. Wani S, Kaul D, Mavuduru RS, Kakkar N, Bhatia A. Urinary­exosomal miR­
2909: a novel pathognomonic trait of prostate cancer severity. J Biotechnol 
(2017) 259:135–9. doi:10.1016/j.jbiotec.2017.07.029 
60. Bryzgunova OE, Zaripov MM, Skvortsova TE, Lekchnov EA, Grigor’eva AE, 
Zaporozhchenko IA, et al. Comparative study of extracellular vesicles from 
the urine of healthy individuals and prostate cancer patients. PLoS One (2016) 
11(6):e0157566. doi:10.1371/journal.pone.0157566 
61. Foj L, Ferrer F, Serra M, Arévalo A, Gavagnach M, Giménez N, et al. Exosomal 
and non­exosomal urinary miRNAs in prostate cancer detection and prog­
nosis. Prostate (2017) 77(6):573–83. doi:10.1002/pros.23295 
62. Hosseini­Beheshti E, Choi W, Weiswald LB, Kharmate G, Ghaffari M, 
Roshan­Moniri M, et  al. Exosomes confer pro­survival signals to alter the 
phenotype of prostate cells in their surrounding environment. Oncotarget 
(2016) 7(12):14639–58. doi:10.18632/oncotarget.7052 
63. Karlsson T, Lundholm M, Widmark A, Persson E. Tumor cell­derived 
exosomes from the prostate cancer cell line TRAMP­C1 impair osteoclast for­
mation and differentiation. PLoS One (2016) 11(11):e0166284. doi:10.1371/
journal.pone.0166284 
64. Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, et al. 
Exosomes secreted under hypoxia enhance invasiveness and stemness of 
prostate cancer cells by targeting adherens junction molecules. Mol Carcinog 
(2015) 54(7):554–65. doi:10.1002/mc.22124 
65. Sánchez CA, Andahur EI, Valenzuela R, Castellón EA, Fullá JA, Ramos CG, 
et al. Exosomes from bulk and stem cells from human prostate cancer have 
a differential microRNA content that contributes cooperatively over local 
and pre­metastatic niche. Oncotarget (2016) 7(4):3993–4008. doi:10.18632/
oncotarget.6540 
66. Lin LC, Gao AC, Lai CH, Hsieh JT, Lin H. Induction of neuroendocrine 
differentiation in castration resistant prostate cancer cells by adipocyte differ­
entiation­related protein (ADRP) delivered by exosomes. Cancer Lett (2017) 
391:74–82. doi:10.1016/j.canlet.2017.01.018 
67. Salimu J, Webber J, Gurney M, Al­Taei S, Clayton A, Tabi Z. Dominant 
immunosuppression of dendritic cell function by prostate­cancer­derived 
exosomes. J Extracell Vesicles (2017) 6(1):1368823. doi:10.1080/20013078.20
17.1368823 
68. Lundholm M, Schröder M, Nagaeva O, Baranov V, Widmark A, Mincheva­
Nilsson L, et  al. Prostate tumor­derived exosomes down­regulate NKG2D 
expression on natural killer cells and CD8+ T cells: mechanism of immune 
evasion. PLoS One (2014) 9(9):e108925. doi:10.1371/journal.pone.0108925 
69. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et  al.  
Gene expression analysis of human prostate carcinoma during hormonal ther­
apy identifies androgen­responsive genes and mechanisms of therapy resis­
tance. Am J Pathol (2004) 164:217–27. doi:10.1016/S0002­9440(10)63112­4 
70. Soekmadji C, Riches JD, Russell PJ, Ruelcke JE, McPherson S, Wang C, et al. 
Modulation of paracrine signaling by CD9 positive small extracellular vesicles 
mediates cellular growth of androgen deprived prostate cancer. Oncotarget 
(2016) 8:52237–55. doi:10.18632/oncotarget.11111 
71. Soekmadji C, Corcoran NM, Oleinikova I, Jovanovic L; Australian Prostate 
Cancer Collaboration BioResource, Ramm GA, et al. Extracellular vesicles 
9Giulietti et al. Small EVs in PCa
Frontiers in Oncology | www.frontiersin.org June 2018 | Volume 8 | Article 221
for personalized therapy decision support in advanced metastatic cancers 
and its potential impact for prostate cancer. Prostate (2017) 77:1416–23. 
doi:10.1002/pros.23403 
72. Mentkowski KI, Snitzer JD, Rusnak S, Lang JK. Therapeutic potential of 
engineered extracellular vesicles. AAPS J (2018) 20(3):50. doi:10.1208/
s12248­018­0211­z 
73. Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, et  al. The 
detection of androgen receptor splice variant 7 in plasma­derived exosomal 
RNA strongly predicts resistance to hormonal therapy in metastatic prostate 
cancer patients. Eur Uro (2017) 71(4):680–7. doi:10.1016/j.eururo.2016. 
08.012 
74. Li J, Yang X, Guan H, Mizokami A, Keller ET, Xu X, et al. Exosome­derived 
microRNAs contribute to prostate cancer chemoresistance. Int J Oncol (2016) 
49(2):838–46. doi:10.3892/ijo.2016.3560 
75. Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, 
Fonseca P, et al. Molecular profiling of prostate cancer derived exosomes may 
reveal a predictive signature for response to docetaxel. Oncotarget (2015) 
6(25):21740–54. doi:10.18632/oncotarget.3226 
76. Corcoran C, Rani S, O’Brien K, O’Neill A, Prencipe M, Sheikh R, et  al. 
Docetaxel­resistance in prostate cancer: evaluating associated phenotypic 
changes and potential for resistance transfer via exosomes. PLoS One (2012) 
7(12):e50999. doi:10.1371/journal.pone.0050999 
77. Kawakami K, Fujita Y, Kato T, Mizutani K, Kameyama K, Tsumoto H, et al. 
Integrin β4 and vinculin contained in exosomes are potential markers for 
progression of prostate cancer associated with taxane­resistance. Int J Oncol 
(2015) 47(1):384–90. doi:10.3892/ijo.2015.3011 
78. Kato T, Mizutani K, Kameyama K, Kawakami K, Fujita Y, Nakane K, et al. 
Serum exosomal P­glycoprotein is a potential marker to diagnose docetaxel 
resistance and select a taxoid for patients with prostate cancer. Urol Oncol 
(2015) 33(9):.e15–20. doi:10.1016/j.urolonc.2015.04.019 
79. Lee EY, Park KS, Yoon YJ, Lee J, Moon HG, Jang SC, et al. Therapeutic effects 
of autologous tumor­derived nanovesicles on melanoma growth and meta­
stasis. PLoS One (2012) 7:e33330. doi:10.1371/journal.pone.0033330 
80. György B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications 
of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol 
Toxicol (2015) 55:439–64. doi:10.1146/annurev­pharmtox­010814­124630 
81. Simpson RJ, Mathivanan S. Extracellular microvesicles: the need for inter­
nationally recognised nomenclature and stringent purification criteria. 
J Proteomics Bioinform (2012) 5:ii–ii. doi:10.4172/jpb.10000e10 
82. Yáñez­Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, et al. 
Biological properties of EVs and their physiological functions. J Extracell 
Vesicles (2015) 4:27066. doi:10.3402/jev.v4.27066 
83. Wu Y, Deng W, Klinke DJ. Exosomes: improved methods to characterize 
their morphology, RNA content, and surface protein biomarkers. Analyst 
(2015) 140(19):6631–42. doi:10.1039/c5an00688k 
84. Ruivo CF, Adem B, Silva M, Melo SA. The biology of cancer exosomes: 
insights and new perspectives. Cancer Res (2017) 77(23):6480–8. doi:10.1158/ 
0008­5472.CAN­17­0994 
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2018 Giulietti, Santoni, Cimadamore, Carrozza, Piva, Cheng, Lopez-
Beltran, Scarpelli, Battelli and Montironi. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) and the copyright owner are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, distribu-
tion or reproduction is permitted which does not comply with these terms.
